Improving Medication Adherence in Cardiometabolic Disease: Practical and Regulatory Implications

Area of Science:

• Cardiovascular Medicine
• Health Services Research
• Regulatory Science

Background:

• Medication nonadherence is a significant issue in cardiovascular disease (CVD), leading to substantial preventable mortality.
• Only about half of CVD patients consistently adhere to prescribed life-saving medications.
• Current focus is on the impact of labeling and education on medication adherence.

Purpose of the Study:

• To summarize the scope of CVD nonadherence.
• To describe U.S. Food and Drug Administration (FDA) initiatives related to adherence.
• To identify targets for improving medication adherence in CVD patients.

Main Methods:

• Review of current literature on CVD nonadherence.
• Analysis of FDA initiatives and their potential impact.
• Identification of key adherence factors, methods, and technological applications.
• Exploration of collaborative research areas for adherence improvement.

Main Results:

• Medication nonadherence contributes to approximately 125,000 preventable deaths annually in the U.S.
• Key areas for improvement include monitoring methods, evidence base, patient/provider engagement, and health disparities.
• Technological applications can aid in simplifying regimens and enhancing adherence.

Conclusions:

• Collaborative efforts between regulatory bodies (FDA) and the clinical community are crucial for reducing CVD nonadherence.
• Aligning FDA's information dissemination with clinical practice can improve medication adherence.
• Improved adherence has the potential to significantly reduce CVD death and disability.